Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice

Bibliography

• Colman SS, Brod MI, Krishnamurthy A, Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001;23(1):127-45
   PubMed Web of Science ®Google Scholar
• Taylor FR. Migraine headache: options for acute treatment. Curr Neurol Neurosci Rep 2005;5(2):86-92
   PubMedGoogle Scholar
• Yang ZY, Le Y, Hu TT, Production of ultrafine sumatriptan succinate particles for pulmonary delivery. Pharm Res 2008;25(9):2012-18
   PubMed Web of Science ®Google Scholar
• Dilone E, Bergstrom D, Cabana B, Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. Sumatriptan Lingual Spray Study Group. Headache 2009;49(10):1445-53
   PubMed Web of Science ®Google Scholar
• Dahlof CG. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache Rep 2005;9(3):206-12
   PubMedGoogle Scholar
• Jain SA, Chauk DS, Mahajan HS, Formulation and evaluation of nasal mucoadhesive microspheres of sumatriptan succinate. J Microencapsul 2009;26(8):711-21
   PubMed Web of Science ®Google Scholar
• Bigal ME, Bordini CA, Antoniazzi AL, The Triptans formulations: a critical evaluation. Arq Neuropsiquiatr 2003;61(2-A):313-20
   PubMedGoogle Scholar
• Tfelt-Hansen P, Edvinsson L. Pharmacokinetic and pharmacodynamic variability as possible causes for different drug responses in migraine. A comment. Cephalalgia 2007;27(10):1091-3
   PubMedGoogle Scholar
• Sheshala R, Khan N, Darwis Y. Formulation and optimization of orally disintegrating tablets of sumatriptan succinate. Chem Pharm Bull 2011;59(8):920-8
   PubMedGoogle Scholar
• Shidhaye SS, Saindane NS, Sutar S, Mucoadhesive bilayered patches for administration of sumatriptan succinate. AAPS PharmSciTech 2008;9(3):909-16
   PubMed Web of Science ®Google Scholar
• Balaguer-Fernandez C, Femenia-Font A, Del Rio-Sancho S, Sumatriptan succinate transdermal delivery systems for the treatment of migraine. J Pharm Sci 2008;97(6):2102-9
   PubMed Web of Science ®Google Scholar
• Adelman JU, Adelman RD. Current options for the prevention and treatment of migraine. Clin Ther 2001;23(6):772-88
   PubMedGoogle Scholar
• Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992;43(5):776-98
   PubMedGoogle Scholar
• Asghar MS, Hansen AE, Kapijimpanga T, Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology 2010;75(17):1520-6
   PubMed Web of Science ®Google Scholar
• Jeong HJ, Chenu D, Johnson EE, Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey. Mol Pain 2008;4:54
   PubMedGoogle Scholar
• Lacey LF, Hussey EK, Fowler PA. Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47(6):543-8
   PubMed Web of Science ®Google Scholar
• Fuseau E, Petricoul O, Moore KH, Clinical pharmacokinetics of intranasal sumatriptan. Clin Pharmacokinet 2002;41(11):801-11
   PubMed Web of Science ®Google Scholar
• Dixon CM, Park GR, Tarbit MH. Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver. Biochem Pharmacol 1994;47(7):1253-7
   PubMedGoogle Scholar
• Dixon CM, Saynor DA, Andrew PD, Disposition of sumatriptan in laboratory animals and humans. Drug Metab Dispos 1993;21(5):761-9
   PubMedGoogle Scholar
• Fowler PA, Thomas M, Lacey LF, Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. Cephalalgia 1989;9(Suppl 9):57-62
   PubMedGoogle Scholar
• Rapoport AM, Freitag F, Pearlman SH. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. CNS Drugs 2010;24(11):929-40
   PubMed Web of Science ®Google Scholar
• Ferrari A, Pinetti D, Bertolini A, Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol 2008;64(5):489-95
   PubMedGoogle Scholar
• Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994;47(4):622-51
   PubMedGoogle Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD008615
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD009663
   PubMed Web of Science ®Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2. [Epub ahead of print]
   Google Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2. [Epub ahead of print]
   Google Scholar
• Jelinski SE, Becker WJ, Christie SN, Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci 2006;33(1):73-9
   PubMed Web of Science ®Google Scholar
• Hodge JA, Hodge KD. Ischemic colitis related to sumatriptan overuse. J Am Board Fam Med 2010;23(1):124-7
   PubMedGoogle Scholar
• Ferrari MD, Roon KI, Lipton RB, Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358(9294):1668-75
   PubMed Web of Science ®Google Scholar
• O'Quinn S, Davis RL, Gutterman DL, Prospective large-scale study of the tolerability of subcutaneous sumatriptan injection for acute treatment of migraine. Cephalalgia 1999;19(4):223-31
   PubMed Web of Science ®Google Scholar
• Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002;112(2):135-40
   PubMedGoogle Scholar
• Christoph-Diener H, Ferrari M, Mansbach H; SNAP Database Study Group. Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database. Neurology 2004;63:520-4
   PubMed Web of Science ®Google Scholar
• Weidmann E, Unger J, Blair S, An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations. Clin Ther 2003;25:235-46
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Cady R, Dodick D, Oral sumatriptan for the acute treatment of probable migraine: first randomized, controlled study. Headache 2006;46:115-24
   PubMedGoogle Scholar
• Tfelt-Hansen P, Bach FW, Daugaard D, Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study. J Headache Pain 2006;7:389-94
   PubMedGoogle Scholar
• Savani N, Pfaffenrath V, Rice L, Efficacy, tolerability, and patient satisfaction with 50- and 100-mg sumatriptan tablets in those initially dissatisfied with the efficacy of 50-mg sumatriptan tablets. Clin Ther 2001;23:260-71
   PubMedGoogle Scholar
• Burstein R, Jakubowski M, Collins B. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55:19-26
   PubMed Web of Science ®Google Scholar
• Aurora SK, Barrodale PM, McDonald SA, Revisiting the efficacy of sumatriptan therapy during the aura phase of migraine. Headache 2009;49:1001-4
   PubMed Web of Science ®Google Scholar
• Cady RK, Rubino J, Crummett D, Oral sumatriptan in the treatment of recurrent headache. Arch Fam Med 1994;3:766-72
   PubMedGoogle Scholar
• Rapoport AM, Visser WH, Cutler NR, Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology 1995;45:1505-9
   PubMedGoogle Scholar
• Walls C, Lewis A, Bullman J, Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004;20:803-9
   PubMed Web of Science ®Google Scholar
• Sheftell FD, Dahlof CG, Brandes JL, Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 2005;27:407-17
   PubMed Web of Science ®Google Scholar
• Newman LC, Cady RK, Landy S, Treatment satisfaction and efficacy of the rapid release formulation of sumatriptan 100 mg tablets utilising an early intervention paradigm in patients previously unsatisfied with sumatriptan. Int J Clin Pract 2008;62:1889-99
   PubMed Web of Science ®Google Scholar
• Barbanti P, Carpay JA, Kwong WJ, Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin 2004;20:2021-9
   PubMed Web of Science ®Google Scholar
• Landy SH, McGinnis JE, McDonald SA. Pilot study evaluating preference for 3-mg versus 6-mg subcutaneous sumatriptan. Headache 2005;45:346-9
   PubMedGoogle Scholar
• Wendt J, Cady R, Singer R, A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther 2006;28:517-26
   PubMed Web of Science ®Google Scholar
• Linde M, Mellberg A, Dahlof C. Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 2006;26:113-21
   PubMed Web of Science ®Google Scholar
• Bates D, Ashford E, Dawson R, Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 1994;44:1587-92
   PubMed Web of Science ®Google Scholar
• Burke-Ramirez P, Asgharnejad M, Webster C, Efficacy and tolerability of subcutaneous sumatriptan for acute migraine: a comparison between ethnic groups. Headache 2001;41:873-82
   PubMed Web of Science ®Google Scholar
• Cady RK, Dexter J, Sargent JD, Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993;43:1363-8
   PubMed Web of Science ®Google Scholar
• Schulman EA, Cady RK, Henry D, Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000;75:782-9
   PubMed Web of Science ®Google Scholar
• Freitag FG. Sumatriptan needle-free subcutaneous (Sumavel(®) DosePro™) approved for the acute treatment of migraine, with or without aura, and cluster headaches. Expert Rev Neurother 2011;11:481-90
   PubMed Web of Science ®Google Scholar
• Brandes JL, Cady RK, Freitag FG, Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009;49:1435-44
   PubMed Web of Science ®Google Scholar
• Rothrock JF, Cady RK, Aurora SK, Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Curr Med Res Opin 2011;27:2185-91
   PubMed Web of Science ®Google Scholar
• Ryan R, Elkind A, Baker CC, Sumatriptan nasal spray for the acute treatment of migraine. Neurology 1997;49:1225-30
   PubMed Web of Science ®Google Scholar
• Farmer K, Cady R, Bleiberg J, Sumatriptan nasal spray and cognitive function during migraine: results of an open-label study. Headache 2001;41:377-84
   PubMed Web of Science ®Google Scholar
• Rothner AD, Winner P, Nett R, One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin Ther 2000;22:1533-46
   PubMed Web of Science ®Google Scholar
• Carpay JA, Linssen WH, Koehler PJ, Efficacy of sumatriptan nasal spray in recurrent migrainous headache: an open prospective study. Headache 2003;43:395-9
   PubMed Web of Science ®Google Scholar
• Docekal P, Bartlova L, Ehler E, Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 2010;30:933-42
   PubMedGoogle Scholar
• Winner P, Rothner AD, Saper J, A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000;106:989-97
   PubMed Web of Science ®Google Scholar
• Winner P, Rothner AD, Wooten JD, Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache 2006;46:212-22
   PubMed Web of Science ®Google Scholar
• Ahonen K, Hamalainen ML, Rantala H, Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology 2004;62:883-7
   PubMed Web of Science ®Google Scholar
• Pakalnis A, Kring D, Paolicchi J. Parental satisfaction with sumatriptan nasal spray in childhood migraine. J Child Neurol 2003;18:772-5
   PubMed Web of Science ®Google Scholar
• Goldstein J, Smith TR, Pugach N, A Sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 2012. [Epub ahead of print]
   Google Scholar
• Pierce M, Marbury T, O'Neill C, Zelrix: a novel transdermal formulation of sumatriptan. Headache 2009;49:817-25
   PubMed Web of Science ®Google Scholar
• Dodick DW, Rozen TD, Goadsby PJ, Cluster headache. Cephalalgia 2000;20:787-803
   PubMed Web of Science ®Google Scholar
• Monstad I, Krabbe A, Micieli G, Preemptive oral treatment with sumatriptan during a cluster period. Headache 1995;35:607-13
   PubMed Web of Science ®Google Scholar
• The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991;325:322-6
   PubMed Web of Science ®Google Scholar
• Ekbom K, Monstad I, Prusinski A, Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group. Acta Neurol Scand 1993;88:63-9
   PubMed Web of Science ®Google Scholar
• Gobel H, Lindner V, Heinze A, Acute therapy for cluster headache with sumatriptan: findings of a one-year-long-term study. Neurology 1998;51:908-11
   PubMed Web of Science ®Google Scholar
• Gregor N, Schlesiger C, Akova-Ozturk E, Treatment of cluster headache attacks with less than 6 mg subcutaneous sumatriptan. Headache 2005;45:1069-72
   PubMedGoogle Scholar
• Hardebo JE. Subcutaneous sumatriptan in cluster headache: a time study of the effect on pain and autonomic symptoms. Headache 1993;33:18-21
   PubMedGoogle Scholar
• Rossi P, Lorenzo GD, Formisano R, Subcutaneous sumatriptan induces changes in frequency pattern in cluster headache patients. Headache 2004;44:713-18
   PubMedGoogle Scholar
• Hering-Hanit R. Alteration in nature of cluster headache during subcutaneous administration of sumatriptan. Headache 2000;40:41-4
   PubMedGoogle Scholar
• Ekbom K, Waldenlind E, Cole JA, Sumatriptan in chronic cluster headache: results of continuous treatment for eleven months. Cephalalgia 1992;12:254-6
   PubMed Web of Science ®Google Scholar
• Centonze V, Rossi A, Causarano V, Sumatriptan overuse in episodic cluster headache: lack of adverse events, rebound syndromes, drug dependance and tachyphylaxis. Funct Neurol 2000;15:167-70
   PubMedGoogle Scholar
• Serdar Turhal N. Sumatriptan overdose in episodic cluster headache: a case report of overuse without event. Cephalalgia 2001;21:700
   PubMedGoogle Scholar
• Kallweit U, Sandor PS. Sumatriptan in excessive doses over 15 years in a patient with chronic cluster headache. Headache 2011;51:1546-8
   PubMedGoogle Scholar
• Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 1999;19:769-78
   PubMed Web of Science ®Google Scholar
• Ashford E, Salonen R, Saiers J, Consistency of response to sumatriptan nasal spray across patient subgroups and migraine types. Cephalalgia 1998;18:273-7
   PubMed Web of Science ®Google Scholar
• Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies. Cephalalgia 1999;19:769-78
   PubMed Web of Science ®Google Scholar
• Winner P, Saper JR, Nett R, Sumatriptan nasal spray in the acute treatment of migraine in adolescent migraineurs. Pediatrics 1999;104:694-5
   Google Scholar
• Schuh-Hofer S, Reuter U, Kinze S, Treatment of acute cluster headache with 20 mg sumatriptan nasal spray: an open pilot study. J Neurol 2002;249:94-9
   PubMedGoogle Scholar
• Hardebo JE, Dahlof C. Sumatriptan nasal spray (20 mg/dose) in the acute treatment of cluster headache. Cephalalgia 1998;18:487-9
   PubMed Web of Science ®Google Scholar
• van Vliet JA, Bahra A, Martin V, Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003;60:630-3
   PubMed Web of Science ®Google Scholar
• Johannes CB, Linet MS, Stewart WF, Relationship of headache to phase of the menstrual cycle among young women: a daily dairy study. Neurology 1995;45:1076-82
   PubMed Web of Science ®Google Scholar
• Granella F, Sances G, Allais G, Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24:707-16
   PubMed Web of Science ®Google Scholar
• Nett R, Landy S, Shackelford S, Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102:835-42
   PubMed Web of Science ®Google Scholar
• Schreiber CP, Cady RK. Diagnosis of menstrual headache and an open-label study among those with previously undiagnosed menstrually related migraine to evaluate the efficacy of sumatriptan 100 mg. Clin Ther 2007;29(Suppl):2511-19
   PubMedGoogle Scholar
• Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain 2005;6:81-7
   PubMedGoogle Scholar
• Newman LC, Lipton RB, Lay CL, A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998;51:307-9
   PubMed Web of Science ®Google Scholar
• Mannix LK, Martin VT, Cady RK, Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 2009;114:106-13
   PubMed Web of Science ®Google Scholar
• Cady RK, Diamond ML, Diamond MP, Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache 2011;51:664-73
   PubMed Web of Science ®Google Scholar
• Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993;82:769-72
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Bonellie G, Kangasniemi P, The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol 1995;86:911-16
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Allais G, Nappi RE, Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. Gynecol Endocrinol 2010;26:773-9
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Le H. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. J Headache Pain 2009;10:137-43
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC. Does sumatriptan cross the blood-brain barrier in animals and man? J Headache Pain 2010;11:5-12
   PubMed Web of Science ®Google Scholar
• Mitsikostas DD, Knight YE, Lasalandra M, Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: a mechanism to prevent central sensitization? J Headache Pain 2011;12:411-17
   PubMed Web of Science ®Google Scholar
• Asghar MS, Hansen AE, Larsson HB, Effect of CGRP and sumatriptan on the BOLD response in visual cortex. J Headache Pain 2012;13:159-66
   PubMed Web of Science ®Google Scholar